Delivery Order SPE2DB24D8002-SPE2DB25FJMZK
Award Date
1/15/25
Potential Completion Date
1/16/25
Potential Value
$1.3K
Federal Agency
Defense Logistics Agency
Awardee
Dakota Drug, Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Anoka, MN, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $2,413.34, is for the delivery of ELIQUIS 5 MG TABLET 60S, a pharmaceutical product. The contract is a firm fixed-price delivery order with a period of performance through February 13, 2025. Dakota Drug, Inc. also holds a larger indefinite delivery contract (IDC) with the DLA, valued at $999,999,999.00, as part of the DLA...
This is a federal contract award from the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $1,073.52, is for the delivery of ELIQUIS 2.5 MG TABLET 60S, a pharmaceutical product. The contract has a firm fixed price pricing type and a completion date of February 24, 2025. Dakota Drug, Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA, identified as SPE2DB24D8001, valued at...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $2,754.55, is for the delivery of Eliquis 5 mg tablets. The contract has a firm fixed price pricing type and a performance period ending on May 1, 2024. Dakota Drug, Inc. is a key supplier to the DLA Troop Support Medical division, providing a wide range of pharmaceutical products, medical supplies, and healthcare...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract has a ceiling value of $3,739.66 and is for the delivery of ELIQUIS 5 MG TABLET 60S. This contract is not a set-aside. Dakota Drug, Inc. holds a large Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999.00, as part of the DLA Troop Support Medical's ECAT Generation V Program. This IDC allows the company to provide...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the provision of ELIQUIS 5 MG TABLET 60S. The contract, with a ceiling value of $4,973.50 and a performance period extending through October 30, 2024, is a firm fixed-price delivery order. It is not associated with any set-aside program. Dakota Drug, Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA, identified as...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $3,179.50, is for the delivery of Eliquis 5 mg tablets to support U.S. Armed Forces medical operations. The contract is a firm-fixed-price arrangement with an ultimate completion date of October 31, 2024. Dakota Drug, Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999.00, as part of...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $3,857.60, is for the delivery of ELIQUIS 5 MG TABLET 60S, a pharmaceutical product, to support the DLA Troop Support Medical's medical supply chain operations. The contract has a period of performance through May 30, 2024. Dakota Drug, Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA,...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $2,230.88, is for the delivery of 4562802555 ELIQUIS 5 MG TABLET 60S to support military medical operations. Dakota Drug, Inc. holds a large Indefinite Delivery Contract (IDC) with the DLA, worth up to $999,999,999.00, which allows the company to provide a wide range of pharmaceutical products, medical...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, identified as SPE2DX15D8002|SPE2DX24F2VB1, is for the delivery of ELIQUIS 5 MG TABLET 60S, a pharmaceutical product. The contract has a ceiling value of $6,246.23 and a period of performance through February 22, 2024. Dakota Drug, Inc. is a key supplier for the DLA Troop Support Medical division, holding a...
This is a federal contract award by the Defense Logistics Agency (DLA) Troop Support Medical division to Dakota Drug, Inc., a self-certified small disadvantaged business. The $13,602.16 firm fixed-price delivery order is for the supply of ELIQUIS 5 MG TABLET 60S, a pharmaceutical product. The contract has an ultimate completion date of April 27, 2023. Dakota Drug, Inc. is a key supplier of pharmaceutical products, medical supplies, and healthcare equipment to the U.S. Department of Defense....